Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any
Updated:3/17/2019
Start Date:January 2015
End Date:December 2019
Contact:Sigurd Knaub, PhD
Email:sigurd.knaub@octapharma.com
Phone:41 55 451 2141

Use our guide to learn which trials are right for you!

Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice

Prospective, multinational, non-interventional post-authorisation study to collect additional
clinical data and to ensure consistency in the long-term between the outcome from
pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients)
and routine clinical practice. Besides aspects such as general product safety and efficacy,
there will be a focus on immunogenicity, particularly on inhibitor development. The diagnosis
of FVIII inhibitor will be based on clinical observations and confirmed by FVIII inhibitor
testing in the laboratory.


Inclusion Criteria:

- Haemophilia A (FVIII:C ≤ 2%) based on medical history; at least 100 patients should
have severe haemophilia A (FVIII:C < 1%)

- Male patients of any age

- Previous treatment with a FVIII concentrate for more than 150 EDs

- Availability of detailed documentation (patient diary, log book, etc.) covering either
the last 50 EDs or the last 2 years per patient to confirm treatment modality (i.e.,
prophylaxis, on-demand, recent surgery, or immune tolerance induction)

- Inhibitor negative (< 0.6 BU) at study entry as confirmed by a recovery test with
previous FVIII product and inhibitor test in a central laboratory

- Immunocompetence (CD4+ count > 200/µL), HIV-negative, or having a viral load < 200
particles/µL or < 400,000 copies/mL

- Decision to prescribe Human-cl rhFVIII before enrolment into the study

- Written informed consent by the patient or the patient's parent or legal guardian

Exclusion Criteria:

- Patients treated with any investigational medicinal product (IMP) except FVIII IMP
within 30 days prior to the Screening Visit or patients planning to undergo treatment
with any IMP other than Human-cl rhFVIII are not eligible for enrolment into the
study.
We found this trial at
6
sites
640 Doctor A. Güemes
Salta, 4400
?
mi
from
Salta,
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
6655 Travis Street
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
3121 South Maryland Parkway
Las Vegas, Nevada 89109
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Miami, Florida 33155
?
mi
from
Miami, FL
Click here to add this to my saved trials
New Orleans, Louisiana 70112
?
mi
from
New Orleans, LA
Click here to add this to my saved trials